Sodium Bicarbonate shortage — US supply status & alternatives

Sodium Bicarbonate

—

🇦🇺 AUST R 131067 · PHEBRA PTY LTD

In supply · Australia

4.2% Sodium Bicarbonate Injection, USP8.4% Sodium Bicarbonate Injection, USP8.4 % Sodium Bicarbonate Injection, USP

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇦 CA

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Sodium Bicarbonate
Brand names	4.2% Sodium Bicarbonate Injection, USP, 8.4% Sodium Bicarbonate Injection, USP, 8.4 % Sodium Bicarbonate Injection, USP
Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper
Controlled substance	No
Marketing-authorisation holders	PHEBRA PTY LTD, BELL SONS & COMPANY (DRUGGISTS) LIMITED, MACARTHYS LABORATORIES LIMITED, B. BRAUN MELSUNGEN +14 more
Registrations on file	24
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇺🇸 US

US$0.15

Acquisition

🇬🇧 GB

£5.08

Drug Tariff

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

6 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk

Acs Dobfar SPAVm ChemicalsEmnar Pharma Private LTDGlobal Calcium Private LTDAlivus Life Sciences LTDMaithri Drugs Private LTD

Manufacturing countries: Italy, India · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

SODIUM BICARBONATE

PFIZER INC · Aug 2025

Class IIdetails ↗

🇺🇸

SODIUM BICARBONATE

Exela Pharma Sciences LLC · July 2025

Class IIdetails ↗

🇺🇸

SODIUM BICARBONATE

Exela Pharma Sciences LLC · Mar 2025

Class IIdetails ↗

🇺🇸

SODIUM BICARBONATE

Pfizer Inc. · Dec 2023

Class Idetails ↗

🇺🇸

SODIUM BICARBONATE

Exela Pharma Sciences LLC · Oct 2023

Class Idetails ↗

🇺🇸

SODIUM BICARBONATE

Exela Pharma Sciences LLC · Nov 2022

Class Idetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders24 registrations · 18 MA holders

Product	Strength	Form	Market	MA holder	Status
Phebra SODIUM BICARBONATE 8.4% w/v	8.4%	—	🇦🇺 AU	PHEBRA PTY LTD	Active
Boots Sodium Bicarbonate Bp	—	boots	🇬🇧 GB	BELL SONS & COMPANY (DRUGGISTS) LIMITED	Active
SODIUM BICARBONATE INJECTION 8.4%W/V	8.4%	injection	🇬🇧 GB	MACARTHYS LABORATORIES LIMITED	Active
Sodium Bicarbonate 8.4% W/V Solution For Infusion	8.4%	solution	🇬🇧 GB	B. BRAUN MELSUNGEN	Active
Sodium Bicarbonate 1.4% Solution For Infusion	1.4%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Sodium Bicarbonate 2.74% Solution For Infusion	2.74%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Sodium Bicarbonate 1.26% Solution For Infusion	1.26%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Sodium Bicarbonate 4.2% Solution For Infusion	4.2%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Sodium Bicarbonate 8.4% Solution For Infusion	8.4%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
SODIUM BICARBONATE INJECTION 8.4%W/V INJECTION	8.4%	injection	🇬🇧 GB	AURUM PHARMACEUTICALS LIMITED	Active
Sodium Bicarbonate Bp	—	sodium	🇬🇧 GB	LCM LIMITED	Active
SODIUM BICARBONATE 500 MG CAPSULES, HARD	500 MG	capsule	🇬🇧 GB	RELONCHEM LIMITED	Active
SODIUM BICARBONATE 84MG/ML ORAL SOLUTION	84MG	solution	🇬🇧 GB	ROMA PHARMACEUTICALS LIMITED	Active
SODIUM BICARBONATE 500MG CAPSULES	500MG	capsule	🇬🇧 GB	KENT PHARMA UK LIMITED	Active
Sodium Bicarbonate 8.4% W/V Solution For	8.4%	injection	🇬🇧 GB	TORBAY PHARMACEUTICALS LIMITED	Active

+9 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.